Multi-pathway therapeutics in colorectal cancer: Targeting EMT, CSCs, and non-apoptotic cell death for drug resistance reversal

2025 Journal of drug targeting 0 citations

Abstract

Colorectal cancer (CRC) is a leading global malignancy, with therapeutic outcomes hampered by chemoresistance from epithelial-mesenchymal transition (EMT), colorectal cancer stem cells (CR-CSCs), and apoptosis evasion. Evidence highlights the therapeutic value of non-apoptotic cell death pathways such as paraptosis, ferroptosis, cuproptosis, and autophagy as strategies to overcome resistance. This review evaluates natural and synthetic scaffolds targeting EMT-driven chemoresistance in CRC by inducing regulated cell death pathways and disrupting stemness-associated survival mechanisms. Studies from the last decade were analyzed, focusing on EMT regulation, CR-CSC markers (Sox2, Oct4, Nanog), chemoresistance proteins (P-gp, ERCC1), and cell death-inducing agents. Emphasis was placed on compounds modulating Wnt/β-catenin, TGF-β, JAK2/STAT3/GPX4, and p38α pathways. Natural compounds (neferine, ajoene, baicalein, isoliensinine, curcumin analogs) and synthetic drugs (5-FU, oxaliplatin, irinotecan, norcantharidin, cordycepin) modulate EMT and trigger ferroptosis, cuproptosis, paraptosis, and autophagy. Mechanistic pathways include HUWE1-TOMM20 axis, CDH17-LGR5 signaling, and mitochondrial reprogramming under acidic stress. Additionally, c-Fos-driven stemness, p38α-mediated survival, and JAK2/STAT3-regulated GPX4 inhibition were intervention points. Simultaneous targeting of EMT, CR-CSC maintenance, and chemoresistance using multifunctional natural and synthetic agents represents a promising strategy in CRC therapy. Induction of alternative cell death pathways may improve response, minimize relapse, and enable combinatorial regimens for resistant tumors.

Affiliated Institutions

Related Publications

Publication Info

Year
2025
Type
article
Pages
1-43
Citations
0
Access
Closed

External Links

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

0
OpenAlex

Cite This

Jiegang Hu, Zhiwei Tang, Narasimha M. Beeraka et al. (2025). Multi-pathway therapeutics in colorectal cancer: Targeting EMT, CSCs, and non-apoptotic cell death for drug resistance reversal. Journal of drug targeting , 1-43. https://doi.org/10.1080/1061186x.2025.2600679

Identifiers

DOI
10.1080/1061186x.2025.2600679